多靶点趋化因子功能抑制剂的研究进展
作者：刘毅;孙晗笑;
Author：
收稿日期： 年卷（期）页码：2010,25(02):-232-235
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：趋化因子;多靶点;抑制;炎症
Key words：
基金项目：国家自然科学基金资助项目(批准号:30872221)
中文摘要
趋化因子系统作为各种急慢性炎症疾病新的治疗靶点,由于自身的冗余性,使得传统的以单一趋化因子或其受体为靶标的特异性拮抗剂的效果甚微,开发具有多靶点抑制趋化因子功能的药物已成为必然。
参考文献
[1]Horuk R.OPINION Chemokine receptor antagonists:overcoming developmental hurdles[J].Nat Rev Drug Disco,2009,8(1):23-33.
[2]Mantovani A.The chemokine system:redundancy for robust out-puts[J].Immunology Today,1999,20(6):254-257.
[3]Grainger DJ,Reckless J.Broad-spectrum chemokine inhibitors(BSCIs)and their anti-inflammatory effects in vivo[J].Bio-chem Pharmaco,2003,65(7):1027-1034.
[4]Webb LMC,Alcami A.Virally encoded chemokine binding pro-teins[J].Mini-Reviews in Med Chem,2005,5(9):833-848.
[5]Alexander JM,Nelson CA,Berkel V.van,et al.Structural basis of chemokine sequestration by a herpesvirus decoy receptor[J].Cell,2002,111(3):343-356.
[6]Alexander-Brett JM,Fremont DH.Dual GPCR,and GAG mim-icry by the M3chemokine decoy receptor[J].J Experi Med,2007,204(13):3157-3172.
[7]Ezerzer C,Dolgin M,Skovorodnikova J,et al.Chemokine receptor-derived peptides as multi-target drug leads for the treatment of inflammatory diseases[J].Peptides,2009,30(7):1296-1305.
[8]Walters I,Austin C,Austin R,et al.Evaluation of a series of bicy-clic CXCR2antagonists[J].Bioorganic&Med Chem Let,2008,18(2):798-803.
[9]Dwyer MP,Yu YN,Chao JP,et al.Discovery of2-hydroxy-N,N-dimethyl-3-｛2-[[(R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino｝benzamide(SCH527123):A potent,orally bioavailable CX-CR2/CXCR1receptor antagonist[J].J Med Chem,2006,49(26):7603-7606.
[10]Chapman RW,Minnicozzi M,Celly CS,et al.A novel,orally ac-tive CXCR1/2receptor antagonist,sch527123,inhibits neutro-phil recruitment,mucus production,and goblet cell hyperplasia in animal models of pulmonary inflammation[J].J Pharmaco and Exper Therap,2007,322(2):486-493.
[11]Kledal TN,Rosenkilde MM,Coulin F,et al.A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus[J].Sci,1997,277(5332):1656-1659.
[12]Fernandez EJ,Wilken J,Thompson DA,et al.Comparison of the structure of vMIP-II with eotaxin-1,RANTES,and MCP-3suggests a unique mechanism for CCR3activation[J].Biochem,2000,39(42):12837-12844.
[13]Shao WP,Fernandez E,Sachpatzidis A,et al.CCR2and CCR5receptor-binding properties of herpesvirus-8vMIP-II based on sequence analysis and its solution structure[J].Europ J Bio-chem,2001,268(10):2948-2959.
[14]Chen SH,Bacon KB,Li L,et al.In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto(WKY)rats by vMIP-II[J].J Exper Med,1998,188(1):193-198.
[15]Lindow M,Luttichau HR,Schwartz TW.Viral leads for chemokine-modulatory drugs[J].Trends in Pharmaco Sci,2003,24(3):126-130.
[16]Reckless J,Grainger DJ.Identification of oligopeptide sequences which inhibit migration induced by a wide range of chemokines[J].Bioche J,1999,340(3):803-811.
[17]Fox DJ,Reckless SG,Warren,et al.Design,synthesis,and pre-liminary pharmacological evaluation of N-acyl-3-aminogluta-rimides as broad-spectrum chemokine inhibitors in vitro and anti-inflammatory agents in vivo[J].J Med Chemi,2002,45(2):360-370.
[18]Fox DJ,Reckless J,Wilbert SM,et al.Identification of3-(acylamino)azepan-2-ones as stable broad-spectrum chemo-kine inhibitors resistant to metabolism in vivo[J].J Med Chem,2005,48(3):867-874.
[19]Grainger DJ,Reckless J,Fox DJ,et al.Broad spectrum chemokine inhibitors related to NR58-3.14.3[J].Mini-Reviews in Med Chem,2005,5(9):825-832.
【关闭】
